Cargando…

The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1(+) Cells

Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) α as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug roxadustat. Little is known about the effects of roxa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jatho, Aline, Zieseniss, Anke, Brechtel-Curth, Katja, Guo, Jia, Böker, Kai Oliver, Salinas, Gabriela, Wenger, Roland H., Katschinski, Dörthe M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869801/ https://www.ncbi.nlm.nih.gov/pubmed/35203399 http://dx.doi.org/10.3390/cells11040753

Ejemplares similares

Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia
por: Jatho, Aline, et al.
Publicado: (2021)

PB2482: ROXADUSTAT SUPPRESSES ADIPOGENESIS IN HUMAN BMMSC AND PROMOTES EPO PRODUCTION VIA REGULATION OF HIF SIGNALING PATHWAYS
por: Zhang, Jing, et al.
Publicado: (2023)

Hypoxia Modulates Fibroblastic Architecture, Adhesion and Migration: A Role for HIF-1α in Cofilin Regulation and Cytoplasmic Actin Distribution
por: Vogler, Melanie, et al.
Publicado: (2013)

Impaired Ca(2+)-handling in HIF-1α(+/−) mice as a consequence of pressure overload
por: Silter, Monique, et al.
Publicado: (2009)

Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia
por: You, Xiaoe, et al.
Publicado: (2022)

Loss of PHD3 in myeloid cells dampens the inflammatory response and fibrosis after hind-limb ischemia
por: Beneke, Angelika, et al.
Publicado: (2017)

Effect of Roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study
por: Zhang, Lei, et al.
Publicado: (2022)

The Three “Musketairs” – Lasker Prize 2016 goes to the protagonists of hypoxia research
por: Wenger, Roland H, et al.
Publicado: (2016)

Defective Mitochondrial Cardiolipin Remodeling Dampens HIF-1α Expression in Hypoxia
por: Chowdhury, Arpita, et al.
Publicado: (2018)

Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications
por: Fang, Tingting, et al.
Publicado: (2023)

Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
por: Branco-Price, Cristina, et al.
Publicado: (2012)

RhoA Ambivalently Controls Prominent Myofibroblast Characteritics by Involving Distinct Signaling Routes
por: Jatho, Aline, et al.
Publicado: (2015)

Renal hypoxia–HIF–PHD–EPO signaling in transition metal nephrotoxicity: friend or foe?
por: Thévenod, Frank, et al.
Publicado: (2022)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss
por: Rauner, Martina, et al.
Publicado: (2021)

HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis
por: Su, Xiaodong, et al.
Publicado: (2022)

Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2016)

O(2) affects mitochondrial functionality ex vivo
por: Nanadikar, Maithily S., et al.
Publicado: (2019)

Correction: HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis
por: Su, Xiaodong, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis
por: Vočanec, Danijela, et al.
Publicado: (2018)

The PTK7-Related Transmembrane Proteins Off-track and Off-track 2 Are Co-receptors for Drosophila Wnt2 Required for Male Fertility
por: Linnemannstöns, Karen, et al.
Publicado: (2014)

EPOS Abstract Book
Publicado: (2022)

Welcome to EPOS 2023
por: Sanpera, Ignacio, et al.
Publicado: (2023)

EPOS Abstract Book
Publicado: (2023)

Frequency of SCA8, SCA10, SCA12, SCA36, FXTAS and C9orf72 repeat expansions in SCA patients negative for the most common SCA subtypes
por: Aydin, Gülsah, et al.
Publicado: (2018)

Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study
por: Choubtum, Lulin, et al.
Publicado: (2015)

Roxadustat and thyroid-stimulating hormone suppression
por: Tokuyama, Atsuyuki, et al.
Publicado: (2021)

IDH3γ functions as a redox switch regulating mitochondrial energy metabolism and contractility in the heart
por: Nanadikar, Maithily S., et al.
Publicado: (2023)

How to pursue EPO in MS
por: Bartels, Claudia, et al.
Publicado: (2017)

Methylation impact analysis of erythropoietin (EPO) Gene to hypoxia inducible factor-1α (HIF-1α) activity
por: Dewi, Firli Rahmah Primula, et al.
Publicado: (2013)

The therapeutic role of Jingchuan tablet on ischaemic cerebral stroke via the HIF-1α/EPO/VEGFA signalling pathway
por: Zhang, Yan, et al.
Publicado: (2022)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Roxadustat: Do we know all the answers?
por: Li, Qiu-Yu, et al.
Publicado: (2023)

Hypoxia and the modulation of the actin cytoskeleton – emerging interrelations
por: Zieseniss, Anke
Publicado: (2014)

Neurogenic and pericytic plasticity of conditionally immortalized cells derived from renal erythropoietin‐producing cells
por: Bapst, Andreas M., et al.
Publicado: (2022)

Reduced EPO receptor expression may contribute to limited pleiotropic effects of EPO during critical illness
por: McCook, O, et al.
Publicado: (2012)

Editorial: an introduction and welcome to Hypoxia
por: Katschinski, Dörthe M
Publicado: (2013)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

An evaluation of the EPOS selective chemistry analyser
por: Hughes, G. J., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_90l4tn4a0cq3p7rsg5hhi9vfp3